Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,272 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06097728 | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma(eVOLVE-Meso) | active not recruiting | Phase 3 | 863 | AstraZenecaINDUSTRY | 21 | Jul 28, 2026 | clinicaltrials |
| NCT05503797 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | recruiting | Phase 2 | 254 | Fore BiotherapeuticsINDUSTRY | 12 | Jul 27, 2026 | clinicaltrials |
| NCT06282159 | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)(MAGIC) | active not recruiting | Phase 2 | 65 | Dianthus TherapeuticsINDUSTRY | 14 | Jul 27, 2026 | clinicaltrials |
| NCT07728188 | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 520 | AbbVieINDUSTRY | 13 | Jul 27, 2026 | clinicaltrials |
| NCT06012435 | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 762 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Jul 23, 2026 | clinicaltrials |
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03) | recruiting | Phase 3 | 400 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Jul 22, 2026 | clinicaltrials |
| NCT05735834 | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients(RITZ) | active not recruiting | Phase 3 | 122 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 8 | Jul 22, 2026 | clinicaltrials |
| NCT07157605 | Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)(SPLENDID) | active not recruiting | — | 94 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 8 | Jul 22, 2026 | clinicaltrials |
| NCT02288962 | Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas | active not recruiting | Phase 3 | 60 | St. Olavs HospitalOTHER | 2 | Jul 21, 2026 | clinicaltrials |
| NCT05416567 | Embolization for Meningioma(e-men) | recruiting | N/A | 30 | St. Olavs HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03885817 | Physically Active During Cancer Treatment (FAKT)(FAKT) | active not recruiting | N/A | 66 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06855121 | The Norwegian Immunotherapy in Multiple Myeloma Study(NIMMS) | recruiting | — | 400 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06907342 | Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)(COSENSE-1) | recruiting | Phase 2 | 148 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04483739 | Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)(IsKia) | active not recruiting | Phase 3 | 302 | European Myeloma Network B.V.NETWORK | 8 | Jul 16, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT06109779 | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | active not recruiting | Phase 3 | 760 | AstraZenecaINDUSTRY | 21 | Jul 10, 2026 | clinicaltrials |
| NCT03568461 | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma(ELARA) | completed | Phase 2 | 98 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 9, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT07344779 | A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice(ROAD) | active not recruiting | — | 1,600 | BayerINDUSTRY | 16 | Jul 7, 2026 | clinicaltrials |
| NCT06356129 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma(GOLSEEK-1) | active not recruiting | Phase 3 | 850 | CelgeneINDUSTRY | 38 | Jul 6, 2026 | clinicaltrials |
| NCT06578247 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML(QuANTUM-WILD) | active not recruiting | Phase 3 | 700 | Daiichi SankyoINDUSTRY | 28 | Jul 2, 2026 | clinicaltrials |
| NCT06388733 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | active not recruiting | Phase 3 | 450 | Ivy Brain Tumor CenterOTHER | 11 | Jul 1, 2026 | clinicaltrials |
| NCT06440629 | Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)(RA-DRUM) | active not recruiting | Phase 4 | 387 | Diakonhjemmet HospitalOTHER | 6 | Jul 1, 2026 | clinicaltrials |
| NCT06206785 | Resting Energy Expenditure in Palliative Cancer Patients(REPAT) | active not recruiting | — | 160 | Norwegian University of Science and TechnologyOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 111 | AmgenINDUSTRY | 24 | Jun 26, 2026 | clinicaltrials |
| NCT06716814 | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa(LIBERTY) | recruiting | Phase 3 | 104 | Swedish Orphan BiovitrumINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT01570010 | The Norwegian Dietary Guidelines and Colorectal Cancer Survival Study(CRC-NORDIET) | active not recruiting | N/A | 503 | University of OsloOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04509700 | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | active not recruiting | Phase 2 | 112 | Incyte CorporationINDUSTRY | 17 | Jun 25, 2026 | clinicaltrials |
| NCT07150104 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 8 | Jun 25, 2026 | clinicaltrials |
| NCT07217184 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 11 | Jun 25, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT03651128 | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)(KarMMa-3) | completed | Phase 3 | 386 | CelgeneINDUSTRY | 13 | Jun 22, 2026 | clinicaltrials |
| NCT04475939 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer(ZEAL-1L) | completed | Phase 3 | 666 | GlaxoSmithKlineINDUSTRY | 27 | Jun 18, 2026 | clinicaltrials |
| NCT05644080 | 68Ga/177Lu-PSMA Theranostics in Recurrent Grade 3 and Grade 4 Glioma | completed | N/A | 10 | St. Olavs HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | recruiting | Phase 1 / Phase 2 | 258 | SanofiINDUSTRY | 10 | Jun 16, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT07651878 | Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment | recruiting | Phase 1 | 24 | MendusINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06326190 | 177Lu-DOTATATE for Recurrent Meningioma(LUMEN-1) | recruiting | Phase 2 | 136 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jun 15, 2026 | clinicaltrials |
| NCT03570892 | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma(BELINDA) | completed | Phase 3 | 330 | Novartis PharmaceuticalsINDUSTRY | 18 | Jun 12, 2026 | clinicaltrials |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy(Viale-a) | active not recruiting | Phase 3 | 443 | AbbVieINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT04607421 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 841 | PfizerINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT03301220 | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma | completed | Phase 3 | 390 | Janssen Research & Development, LLCINDUSTRY | 24 | Jun 8, 2026 | clinicaltrials |
| NCT05904119 | Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study(LEGATO) | recruiting | Phase 3 | 411 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Jun 8, 2026 | clinicaltrials |
| NCT02541435 | Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer | recruiting | — | 1,600 | St. Olavs HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05361434 | A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults(CaboCombo) | completed | — | 311 | IpsenINDUSTRY | 8 | Jun 1, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials